A Nordic research led by the researchers of the Karolinska Institute in Sweden and the results issued in the Journal BMJ stated that the usage of a new type of drug group referred to as SGLT2 for treating type 2 diabetes can cause serious diabetic complications and also increases the risk for lower- limb amputation. The number of patients suffering from diabetes is nearly 1 out of 10 people after the age of 18 all over the globe and is predicted to grow eventually. Patients that suffer from diabetes experience several problems and complexities all over the body mainly eye, heart, kidney as well as blood vessels and nerves disorders. The use of SGLT2 drug increased with a great speed in the recent years, as it also reduces the chances of inculcating cardiovascular diseases according to some researches while the adverse impacts of the drug were still unknown. The research held was carried out with the help of collaborations between the NTNU in Norway, Karolinska Institute in Sweden, Statens Serum Institute in Denmark with the Swedish National Diabetes Register. The study involved going through several registered on the national level to obtain information about the prescription of the drugs, information about the diseases and medical data of about 34 thousand patients from Denmark and Sweden from the year 2013 to 2016. The information helped doctors figure about the relation between the drug SGLT2 and seven adverse effects which were associated to the drug for long. The doctors prescribed a group of patients with a drug to figure out the side effects better. The results depicted a significant role of the SGLT2 drug in causing higher risk for the lower limb amputation and complications for the diabetic ketoacidosis and some other side effects that were absolutely minor while there no relation between the other five effects that were associated with the drug like acute kidney, venous thromboembolism, bone fracture, serious urinary tract infection and acute pancreatitis.